The latest research news in genetics and genomics.
New data now suggests that evaluating PD-L2 levels might better predict response to PD-1 targeting immune-oncology drugs than current tests that only measure PD-L1.
Positive Bioscience will offer Biodesix's liquid biopsy tests for non-small cell lung cancer in India.
The company plans to use the funds to support expansion of its commercial footprint by increasing sales and marketing efforts and new technology development.
The funds come from an equity investment by Chinese health firm iCarbonX announced at the beginning of the year as part of a partnership between the companies.
The investment bank also assigned a price target of $194 per share to the life science tools and diagnostics firm's stock.
